De Facto Communications Wins Trade Communications Brief from Plasticell
The communications programme is focused primarily on generating news coverage through tailored press release announcements, as well as selective company profiles, product and thought leadership focused features exposure. Target media comprises UK, pan European and international print and on-line biotech publications.
De Facto, which specialises in life science, biotech and pharma PR, will raise Plasticell’s profile amongst key target audiences in the life science sector, positioning the company as a proactive leader in its field and an industry innovator. Technological messaging is focused on the Company’s proprietory Combinatorial Cell Culture™ (CombiCultTM) technology, which enables cell culture variables to be tested in random combinations to discover optimal laboratory protocols for the differentiation of adult or pluripotent stem cells. At the same time, corporate messaging is focused on the Company’s success. Since October of this year alone, the company has attracted industry partnering agreements with Sigma Aldrich and UCB.
De Facto Associate Director, Tristan Jervis, who leads the account, commented: “This is a terrific win for our agency, especially as Plasticell is a niche player in the stem cell differentiation market. The company deserves full industry recognition for its unparrelled contribution to the sector. We look forward to playing our part in raising the company’s profile through media coverage and highlighting the strength of its offering to target audiences through out the life sciences sector.”
Dr. Yen Choo, CEO of Plasticell, added: “We are pleased to have engaged De Facto Communications to expand our international profile, and to build and enhance industry awareness of our unique stem cell differentiation technology, together with our corporate strengths, appeal and achievements. We were impressed by De Facto’s track record for servicing clients with the utmost diligence and for maintaining high consistency in coverage results. Furthermore, we were attracted by their ability to edit and communicate complex science using clear and eye catching language, together with their strong network of media contacts through out the biotechnology and broader healthcare sectors”.
For further information please contact Tristan Jervis, Associate Director, De Facto communications on 00 44 207 861 3019 or t.jervis@defacto.com